Trinity BiotechTRIB -1.63%26 Receivables Turnover is 2.51 as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 26/100 and a GF Value™ of $0.74 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 74.6% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Trinity Biotech's Revenue for the
six
months ended in Dec. 2025 was $25.38 Mil. Trinity Biotech's average Accounts Receivable for the
six
months ended in Dec. 2025 was $10.13 Mil.
Hence, Trinity Biotech's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.51.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Trinity Biotech Receivables Turnover Related Terms
Trinity Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TRIB vs AIDX, NVNO, STME: Receivables Turnover Comparison
For the Medical Devices subindustry, Trinity Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trinity Biotech (TRIB) has a Receivables Turnover of 2.51 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #605 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 74.6%.
Is Trinity Biotech's Receivables Turnover too high?
Trinity Biotech's current Receivables Turnover is 2.51. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Trinity Biotech's value of 2.51 is 54.4% below this industry median. Based on the distribution chart, Trinity Biotech ranks #605 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Trinity Biotech has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Receivables Turnover compare to AIDX and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #605 out of 811 companies for Receivables Turnover. This places Trinity Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.51. Trinity Biotech's value of 2.51 is 54.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trinity Biotech's current Receivables Turnover of 2.51 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current Receivables Turnover is 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.74, compared to a current price of $0.38 — trading 48.3% below its estimated fair value. The current Receivables Turnover is 2.51 and 54.4% below the Medical Devices & Instruments industry median of 5.51. Trinity Biotech's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Receivables Turnover is 2.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.38 is trading 48.3% below its estimated GF Value™ of $0.74.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Receivables Turnover: 2.51
GF Value™: $0.74 vs. price of $0.38 (48.3% below fair value)
Industry Position: 54.4% below the Medical Devices & Instruments median (#605 of 811)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
26GF Score
Get the complete analysis for TRIB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
